Literature DB >> 20683902

Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer.

Karen M Bussard1, David J Venzon, Andrea M Mastro.   

Abstract

Metastatic breast cancer cells co-opt the cells of the bone to increase their production of inflammatory cytokines. Here, we sought to identify key cytokines expressed by osteoblasts in vitro and in vivo in the presence of MDA-MB-231 metastatic breast cancer cells, including a bone-seeking variant. We hypothesized that osteoblast-derived cytokines increase in the presence of metastatic breast cancer cell conditioned medium (CM), act as chemoattractants for cancer cells, and enhance osteoclast formation. We detected increases in the concentrations of osteoblast-derived IL-6, MCP-1, VEGF, MIP-2, and KC in vitro in culture supernatants from MC3T3-E1 cells in the presence of metastatic breast cancer cell CM and from cancer-bearing femurs ex vivo. A comparison of cancer cell- and osteoblast-derived cytokines revealed that while breast cancer cells expressed the same or equivalent cytokines as the osteoblasts, the breast cancer cells only produced picogram quantities of MCP-1; osteoblasts expressed nanogram amounts. Bone-derived MCP-1 increased in the proximal metaphysis, an area where breast cancer cells preferentially trafficked following intracardiac inoculation in athymic mice. An MDA-MB-231 bone-seeking variant was not different from parental lines. Osteoblast CM was a potent chemoattractant for metastatic breast cancer cells. Furthermore, culture supernatants of osteoblasts treated with breast cancer cell CM enhanced osteoclast formation. These findings suggest that bone metastatic breast cancer cells utilize osteoblast-derived cytokines to facilitate breast cancer cell colonization and survival upon arrival in the bone microenvironment.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683902      PMCID: PMC3654838          DOI: 10.1002/jcb.22799

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  40 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Localization of osteoblast inflammatory cytokines MCP-1 and VEGF to the matrix of the trabecula of the femur, a target area for metastatic breast cancer cell colonization.

Authors:  Karen M Bussard; Noriaki Okita; Neil Sharkey; Thomas Neuberger; Andrew Webb; Andrea M Mastro
Journal:  Clin Exp Metastasis       Date:  2010-05-06       Impact factor: 5.150

Review 3.  The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts.

Authors:  D T Graves; Y Jiang; A J Valente
Journal:  Front Biosci       Date:  1999-07-01

4.  Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

Authors:  R Cailleau; M Olivé; Q V Cruciger
Journal:  In Vitro       Date:  1978-11

5.  Kinetics of metastatic breast cancer cell trafficking in bone.

Authors:  Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

6.  BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process.

Authors:  Pushkar A Phadke; Kedar S Vaidya; Kevin T Nash; Douglas R Hurst; Danny R Welch
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

7.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A.

Authors:  Patrizia Scapini; Monica Morini; Cristina Tecchio; Simona Minghelli; Emma Di Carlo; Elena Tanghetti; Adriana Albini; Clifford Lowell; Giorgio Berton; Douglas M Noonan; Marco A Cassatella
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

9.  Differential effects of interleukin-6 receptor activation on intracellular signaling and bone resorption by isolated rat osteoclasts.

Authors:  B S Moonga; O A Adebanjo; H-J Wang; S Li; X B Wu; B Troen; A Inzerillo; E Abe; C Minkin; C L-H Huang; M Zaidi
Journal:  J Endocrinol       Date:  2002-06       Impact factor: 4.286

10.  Breakdown of the endothelial barrier function in tumor cell transmigration.

Authors:  Claudia Tanja Mierke; Daniel Paranhos Zitterbart; Philip Kollmannsberger; Carina Raupach; Ursula Schlötzer-Schrehardt; Tamme Weyert Goecke; Jürgen Behrens; Ben Fabry
Journal:  Biophys J       Date:  2007-12-20       Impact factor: 4.033

View more
  41 in total

1.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

2.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

3.  Three-Dimensional Mechanical Loading Modulates the Osteogenic Response of Mesenchymal Stem Cells to Tumor-Derived Soluble Signals.

Authors:  Maureen E Lynch; Aaron E Chiou; Min Joon Lee; Stephen C Marcott; Praveen V Polamraju; Yeonkyung Lee; Claudia Fischbach
Journal:  Tissue Eng Part A       Date:  2016-08-01       Impact factor: 3.845

4.  CCL2, CCL5, and IGF-1 participate in the immunomodulation of osteogenesis during M1/M2 transition in vitro.

Authors:  Luis A Córdova; Florence Loi; Tzu-Hua Lin; Emmanuel Gibon; Jukka Pajarinen; Akira Nabeshima; Laura Lu; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2017-08-21       Impact factor: 4.396

5.  Monitoring dynamic interactions between breast cancer cells and human bone tissue in a co-culture model.

Authors:  Christopher H Contag; Wen-Rong Lie; Marie C Bammer; Jonathan W Hardy; Tobi L Schmidt; William J Maloney; Bonnie L King
Journal:  Mol Imaging Biol       Date:  2014-04       Impact factor: 3.488

6.  Methods for culturing human femur tissue explants to study breast cancer cell colonization of the metastatic niche.

Authors:  Zachary S Templeton; Michael H Bachmann; Rajiv V Alluri; William J Maloney; Christopher H Contag; Bonnie L King
Journal:  J Vis Exp       Date:  2015-03-15       Impact factor: 1.355

7.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 8.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

Review 9.  Biomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations.

Authors:  Maureen E Lynch; Claudia Fischbach
Journal:  Adv Drug Deliv Rev       Date:  2014-08-29       Impact factor: 15.470

10.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Authors:  Yu Zheng; Dennis Basel; Shu-Oi Chow; Colette Fong-Yee; Sarah Kim; Frank Buttgereit; Colin R Dunstan; Hong Zhou; Markus J Seibel
Journal:  Clin Exp Metastasis       Date:  2014-09-16       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.